Bischof Dr. Karl Golser Stiftung » Referenzen 

Referenzen   versione testuale

[1] Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. 2015;372(3):249-63.
[2] Bower JH, Maraganore DM, McDonnell SK, et al. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology. 1997;49(5):1284-8.
[3] Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999;354(9192):1771-5.
[4] Wenning GK, Fanculli A. Multiple-system atrophy. Springer Verlag 2014; ISBN: 978-3-7091-0686-0
[5] Köllensperger M, Geser F, Ndayisaba JP, et al.  Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord. 2010;25(15):2604-12.
[6] Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163(1):94-8.
[7] Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670-6.
[8], 2. September 2015.
[9] Wenning GK, Working Group on Atypical Parkinsonism of the Austrian Parkinson's Society. Placebo-controlled trial of amantadine in multiple-system atrophy. Clin Neuropharmacol. 2005;28(5):225-7.
[10] Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95(1):38-48.
[11] Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277(13):1046-51.
[12] Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51(1):120-4.
[13] Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med. 1995;99(6):604-10.
[14] Ramirez CE, Okamoto LE, Arnold AC, et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2014;64(6):1235-40.
[15] Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology. 1999;53(9):2151-7.
[16] Kaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003;108(6):724-8.
[17] Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83(4):328-35.
[18] Biaggioni I, Freeman R, Mathias CJ, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015;65(1):101-7.
[19] van Lieshout JJ, ten Harkel AD, Wieling W. Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure. Clin Auton Res. 2000;10(1):35-42.
[20] Chobanian AV, Volicer L, Tifft CP, et al. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med. 1979 Jul 12;301(2):68-73.
[21] Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006; 63(4):513-8.
[22] Shibao C, Okamoto LE, Gamboa A, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2010;56(5):847-51.
[23] Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol. 2003;20(6):392-9.
[24] Hussain IF, Brady CM, Swinn MJ, et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001;71(3):371-4.
[25] Mancini F, Zangaglia R, Cristina S, et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord. 2003;18(6):685-8.
[26] Holmberg B, Johansson JO, Poewe W, et al. Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord. 2007;22(8):1138-44.
[27] Dodel R, Spottke A, Gerhard A, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord. 2010;25(1):97-107.
[28] Bensimon G, Ludolph A, Agid Y, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009;132(Pt 1):156-71.
[29] Saccà F, Marsili A, Quarantelli M, et al. A randomized clinical trial of lithium in multiple system atrophy. J Neurol. 2013;260(2):458-61.
[30] Low PA, Robertson D, Gilman S, et al. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(3):268-75.
[31] Poewe W, Seppi K, Fitzer-Attas CJ, et al. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol. 2015;14(2):145-52.
[32] Lee PH, Lee JE, Kim HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol. 2012;72(1):32-40.
[36] Grehl H, Reinhardt F. Checkliste Neurologie. Thieme 2013, 5.Auflage; ISBN: 978-3-13-126275-2
[37] Savica R, Grossardt BR, Bower JH, et al. Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol. 2013;70(11):1396-402.
[38] Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005;34(6):561-6.
[39] McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2005;65(12):1863–72.
[40] Colosimo C, Riley DE, Wenning GK. Handbook of Atypical Parkinsonism. Cambridge University Press 2011, ISBN 978-0-521-11197-3
[41] Molloy S, McKeith IG, O'Brien JT, et al. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005;76(9):1200-3.
[42] Molloy SA, Rowan EN, O'Brien JT, et al. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006;77(12):1323-8.
[43] Vann Jones SA, O'Brien JT. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Psychol Med. 2014;44(4):673-83.
[48] Chiò A, Magnani C, Schiffer D. Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord. 1998;13(3):400-5.
[49] Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005; 128 (Pt 6) 1247-58.
[50] Golbe LI, Progressive supranuclear palsy. Semin Neurol. 2014;34(2):151-9.
[51] Tsai RM, Boxer AL. Clinical trials: past, current, and future for atypical Parkinsonian syndromes. Semin Neurol. 2014;34(2):225-34.
[52] Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47 (1) 1-9.
[53] Klingelhöfer J, Berthele A. Klinikfaden Neurologie. Elsevier Germany Munich, 4. Auflage, 2009; ISBN: 978-3-437-23142-1
[54] Ward AB, Molenaers G, Colosimo C, et al. Clinical value of botulinum toxin in neurological indications. Eur J Neurol. 2006;13 Suppl 4:20-6.
[55] Poujois A, Vidailhet M, Trocello JM, et al. Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy. Eur J Neurol. 2007;14(9):1060-2.
[56] Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57(3):467-73.
[57] Liepelt I, Gaenslen A, Godau J, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement. 2010;6(1):70-4.
[58] Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13(7):676-85.
[59] Tolosa E, Litvan I, Höglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29(4):470-8.
[60] Nübling G, Paul S, Hensler M, et al. The PROSPERA study: a randomized, placebo-controlled, single center trial to evaluate the safety and efficacy of rasagiline in progressive supranuclear palsy [abstr]. Jahrestagung der Deutschen Gesellschaft für Neurologie. Dresden 2013.
[61] Stamelou M, Reuss A, Pilatus U, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008; 23(7):942-9.
[62] Apetauerova D, Standaert DG, Yacoubian T, et al. Effects of coenzyme Q10 in PSP, a multicenter, randomized, placebo-controlled, double-blind study [abstr]. Mov Disord 2014;29(Suppl 1):265.
[63] Giordano R, Canesi M, Isalberti M, et al. Autologous mesenchymal stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study. J Transl Med. 2014;12:14.
[68] Winter Y, Bezdolnyy Y, Katunina E , et al. Incidence of Parkinson's disease and atypical parkinsonism: Russian population-based study. Mov Disord 2010; 25 (3) 349-56.
[69] Osaki Y, Morita Y, Kuwahara T, Miyano I, Doi Y. Prevalence of Parkinson's disease and atypical parkinsonian syndromes in a rural Japanese district. Acta Neurol Scand 2011; 124 (3) 182-7.
[70] Togasaki DM, Tanner CM. Epidemiologic aspects. Adv Neurol 2000; 82: 53-9.
[71] Kouri N, Murray ME, Hassan A , et al. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain 2011; 134 (Pt 11) 3264-75.
[72] Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80 (5) 496-503.
[73] Grijalvo-Perez AM, Litvan I. Corticobasal Degeneration. Semin Neurol 2014; 34(02): 160-73.